Mirabella Financial Services LLP Buys 1,600,000 Shares of MaxCyte, Inc. $MXCT

Mirabella Financial Services LLP lifted its stake in MaxCyte, Inc. (NASDAQ:MXCT) by 24.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,200,000 shares of the company’s stock after purchasing an additional 1,600,000 shares during the quarter. MaxCyte accounts for approximately 0.4% of Mirabella Financial Services LLP’s holdings, making the stock its 17th biggest position. Mirabella Financial Services LLP owned approximately 0.08% of MaxCyte worth $12,956,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of MXCT. Prudential Financial Inc. purchased a new stake in shares of MaxCyte during the 2nd quarter valued at about $26,000. State of Wyoming bought a new position in shares of MaxCyte in the second quarter worth about $38,000. Dynamic Technology Lab Private Ltd bought a new position in shares of MaxCyte in the second quarter worth about $40,000. Kwmg LLC lifted its position in shares of MaxCyte by 75.8% during the 3rd quarter. Kwmg LLC now owns 25,833 shares of the company’s stock valued at $41,000 after buying an additional 11,135 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its stake in shares of MaxCyte by 266.6% during the 2nd quarter. BNP Paribas Financial Markets now owns 26,008 shares of the company’s stock valued at $57,000 after acquiring an additional 18,913 shares during the period. Institutional investors own 68.81% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on MXCT. Weiss Ratings reissued a “sell (e+)” rating on shares of MaxCyte in a report on Monday, December 29th. Wall Street Zen upgraded shares of MaxCyte from a “sell” rating to a “hold” rating in a research report on Sunday. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $6.00.

MaxCyte Stock Down 1.1%

Shares of MXCT stock opened at $0.81 on Tuesday. The company’s fifty day simple moving average is $0.96 and its two-hundred day simple moving average is $1.35. MaxCyte, Inc. has a 52 week low of $0.64 and a 52 week high of $3.33. The stock has a market cap of $86.51 million, a P/E ratio of -1.84 and a beta of 1.22.

About MaxCyte

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.